The CCAS EXPERT SUMMIT convened an array of international experts in Barbados on August 27–31, 2017 under the theme “From Care to Cure–Shifting the HIV Paradigm.” The Caribbean Cytometry & Analytical Society (CCAS) partnered with the Joint United Nations Programme on HIV/AIDS (UNAIDS) to deliver a program that reviewed the advances in antiretroviral therapy and the public health benefits accruing from treatment as prevention. Particular emphasis was placed on reexamining stigma and discrimination through a critical appraisal of whether public health messaging and advocacy had kept pace with the advances in medicine. Persistent fear of HIV driving discriminatory behavior was widely reported in different regions and sectors, including the healthcare profession itself; continued fear of the disease was starkly misaligned with the successes of new medical treatments and progress toward the UNAIDS 90-90-90 targets. The summit therefore adopted the mantra “Test-Treat-Defeat” to help engage with the public in a spirit of optimism aimed at creating a more conducive environment for persons to be tested and treated and, thereby, help reduce HIV disease and stigma at the individual and community levels.
Get full access to this article
View all access options for this article.
References
1.
MandyFF, BergeronM, MinkusT: Evolution of leukocyte immunophenotyping as influenced by the HIV/AIDS pandemic: A short history of the development of gating strategies for CD4+ T-cell enumeration. Cytometry, 1997; 30:157–165.
2.
TungJW, HeydariK, TirouvanziamR, et al.: Modern flow cytometry: A practical approach. Clin Lab Med, 2007; 27:453–468, v.
3.
JanossyG, ShapiroH: Simplified cytometry for routine monitoring of infectious diseases. Cytometry B Clin Cytom, 2008; 74Suppl 1:S6–S10.
4.
CrispN: Co-development, innovation and mutual learning—Or how we need to turn the world upside down. Healthc (Amst), 2015; 3:221–224.
5.
MersonM, DennyTN: The global health and diagnostic (flow) cytometry—Breakthroughs in HIV and tuberculosis. Cytometry B Clin Cytom, 2008; 74Suppl 1:S4–S5.
6.
JaniIV, PeterTF: How point-of-care testing could drive innovation in global health. N Engl J Med, 2013; 368:2319–2324.
ParekhBS, KalouMB, AlemnjiG, OuCY, Gershy-DametGM, NkengasongJN: Scaling up HIV rapid testing in developing countries: Comprehensive approach for implementing quality assurance. Am J Clin Pathol, 2010; 134:573–584.
9.
ParekhBS, AnyanwuJ, PatelH, et al.: Dried tube specimens: A simple and cost-effective method for preparation of HIV proficiency testing panels and quality control materials for use in resource-limited settings. J Virol Methods, 2010; 163:295–300.
10.
GranadeTC, NguyenS, KuehlDS, ParekhBS: Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses, 2013; 29:61–67.
11.
ParekhB, DetorioM, ShanmugamV, YufenyuyE, KimA, NkengasongJ: Performance evaluation of Asante™ rapid recency assay for HIV diagnosis and detection of recent infection: Potential for surveillance and prevention. 9th IAS Conference on HIV Science,Paris, France, 2017.
12.
PassaesCP, BruelT, DecalfJ, et al.: Ultrasensitive HIV-1 p24 assay detects single infected cells and differences in reservoir induction by latency reversal agents. J Virol, 2017; 91: pii: e02296-16.
13.
Sexuelle LACdS. Available at https://cliniquelactuel.com/history_clinique-medicale-l-Actuel, accessed May29, 2018.
14.
BeaucheminM, GreenwaldZR, LongpreD, LavoieS, CharestL, ThomasR: HIV over 50: comparison between newly and long-infected individuals. 16th European AIDS Conference, Milan, Italy, 10, 2017. Available at http://www.natap.org/2017/EACS/EACS_71.htm., accessed May29, 2018.
15.
MehrajV, CoxJ, LeboucheB, et al.: Socio-economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015. J Int AIDS Soc, 2018; 21::e25034.
16.
DeJesusE, HaasB, Segal-MaurerS, et al.: Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide (TAF)-based regimen through 96 weeks of treatment. AIDS Res Hum Retroviruses, 2018; 34:337–342.
17.
ReifLK, RiveraV, LouisB, et al.: Community-based HIV and health testing for high-risk adolescents and youth. AIDS Patient Care STDs, 2016; 30:371–378.
18.
LeboucheB, EnglerK, MachoufN, LessardD, ThomasR: Predictors of interest in taking pre-exposure prophylaxis among men who have sex with men who used a rapid HIV-testing site in Montreal (Actuel sur Rue). HIV Med, 2016; 17:152–158.
19.
GreenwaldZR, BeaucheminM, GirardG, et al.: Who opts for daily versus on demand pre-exposure prophylaxis?.Adherence, Miami. 2017. Available at http://www.iapac.org/AdherenceConference/presentations/ADH2017_OA227.pdf, accessed May29, 2018.
20.
PapeJW, LiautaudB, ThomasF, et al.: Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti. N Engl J Med, 1983; 309:945–950.
21.
PapeJW, SeverePD, FitzgeraldDW, et al.: The Haiti research-based model of international public health collaboration: The GHESKIO Centers. J Acquir Immune Defic Syndr, 2014; 65Suppl 1:S5–S9.
22.
PierreS, RivieraV, JeanCP, et al.: Live with the disease like you used to before you knew you were infected: A Qualitative Study among 10-year survivors living with HIV in Haiti. AIDS Patient Care STDs, 2017; 31:145–151.
23.
EsperanceMC, KoenigSP, GuiteauC, et al.: A successful model for rapid triage of symptomatic patients at an HIV testing site in Haiti. Int Health, 2016; 8:96–100.
24.
KoenigSP, DorvilN, DevieuxJG, et al.: Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med, 2017; 14:e1002357.
25.
LinerKJ, RoMJ, 2nd RobertsonKR: HIV, antiretroviral therapies, and the brain. Curr HIV AIDS Rep, 2010; 7:85–91.
26.
RobertsonKR, LamaJR, PilcherC, et al.: Can we afford to wait? ART and the CNS.Conference on Retroviruses and Opportunistic Infections (CROI) Seattle Washington, February 13–16, 2017. Available at www.croiconference.org/sites/default/files/posters-2017/380_Robertson.pdf, accessed May29, 2018.
27.
Integrase and maraviroc intensification in neurocognitive dysfunction (InMIND). Available at https://clinicaltrials.gov/ct2/show/NCT02519777, accessed May29, 2018.
28.
QuinnTC, WawerMJ, SewankamboN, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med, 2000; 342:921–929.
29.
FideliUS, AllenSA, MusondaR, et al.: Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses, 2001; 17:901–910.
30.
CohenMS, ChenYQ, McCauleyM, et al.: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011; 365:493–505.
31.
RodgerAJ, CambianoV, BruunT, et al.: Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA, 2016; 316:171–181.
32.
CohenMS, ChenYQ, McCauleyM, et al.: Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med, 2016; 375:830–839.
33.
GrinsztejnB, HosseinipourMC, RibaudoHJ, et al.: Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: Results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis, 2014; 14:281–290.
34.
CoriA, AylesH, BeyersN, et al.: HPTN 071 (PopART): A cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: Mathematical model. PLoS One, 2014; 9:e84511.
35.
HayesR, AylesH, BeyersN, et al.: HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment—A study protocol for a cluster randomised trial. Trials, 2014; 15:57.
36.
VermundSH, FidlerSJ, AylesH, BeyersN, HayesRJ: Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr, 2013; 63Suppl 2:S221–S227.
37.
HayesR, FidlerS, CoriA, et al.: HIV treatment-as-prevention research: Taking the right road at the crossroads. PLoS Med, 2015; 12:e1001800.
38.
PilcherCD, Ospina-NorvellC, DasguptaA, et al.: The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. J Acquir Immune Defic Syndr, 2017; 74:44–51.
39.
HsiehYH, KelenGD, LaeyendeckerO, KrausCK, QuinnTC, RothmanRE: HIV care continuum for HIV-infected emergency department patients in an inner-city academic Emergency Department. Ann Emerg Med, 2015; 66:69–78.
40.
Global AIDS Update 2016. Available at http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf, accessed May29, 2018.
41.
Global AIDS Update 2017: “Ending AIDS. Progress towards the 90-90-90 targets”: Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf, accessed May29, 2018.
42.
Maheu-GirouxM, VesgaJF, DiabatéS, et al.: Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Cote d'Ivoire: Insights from mathematical modeling. PLoS Med, 2017; 14:e1002321.
43.
LimaVD, St-JeanM, RozadaI, et al.: Progress towards the United Nations 90-90-90 and 95-95-95 targets: The experience in British Columbia, Canada. J Int AIDS Soc, 2017; 20:e25011.
44.
ScottN, StooveM, KellySL, WilsonDP, HellardME: Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia. Clin Infect Dis, 2018; 66; 1019–1023.
45.
WHO validates elimination of mother-to-child transmission of HIV and syphilis in Cuba.2015. Available at www.who.int/mediacentre/news/releases/2015/mtct-hiv-cuba/en/, accessed May29, 2018.
46.
WHO validates elimination of mother-to-child transmission of HIV and syphilis in Armenia, Belarus and the Republic of Moldova.2016. Available at www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2016/june/20160607_PR_EMTCT_Europe, accessed May29, 2018.
47.
Thailand is first country in Asia to eliminate mother-to-child transmission of HIV and syphilis. 2016. Available at www.searo.who.int/mediacentre/releases/2016/1627/en/, accessed May29, 2018.
48.
Six Caribbean territories and states eliminate mother-to-child transmission of HIV and syphilis.2017. Available at www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2017/december/20171201_caribbean, accessed May29, 2018.
49.
AliyuMH, BlevinsM, AudetCM, et al.: Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: A cluster-randomised controlled trial. Lancet HIV, 2016; 3:e202–e211.
50.
LogieCH, Lacombe-DuncanA, BrienN, et al.: Barriers and facilitators to HIV testing among young men who have sex with men and transgender women in Kingston, Jamaica: A qualitative study. J Int AIDS Soc, 2017; 20:21385.
51.
StutterheimSE, SickingL, BrandsR, et al.: Patient and provider perspectives on HIV and HIV-related stigma in Dutch health care settings. AIDS Patient Care STDs, 2014; 28:652–665.
52.
ZulligerR, KennedyC, BarringtonC, PerezM, DonastorgY, KerriganD: A multi-level examination of the experiences of female sex workers living with HIV along the continuum of care in the Dominican Republic. Glob Public Health, 2017:1–15.
53.
U = U: Prevention access campaign. Available at https://www.preventionaccess.org/ accessed May29, 2018.
54.
MonteiroS, VillelaW, SoaresP, PinhoA: ‘Protective’ silence surrounding AIDS: Reasons and implications of non-disclosure among pregnant women living with HIV in Rio de Janeiro (Brazil). Glob Public Health 2018; 13:51–64.
55.
Rivera-DiazM, Varas-DiazN, PadillaM, de Los Angeles Vargas-CancelM, SerranoN: Family interaction and social stigmatization of people living with HIV and AIDS in Puerto Rico. Glob Soc Work, 2017; 7:3–26.
56.
AdamsAK, ZamberiaAM: ‘I will take ARVs once my body deteriorates’: An analysis of Swazi men's perceptions and acceptability of Test and Start. Afr J AIDS Res, 2017; 16:295–303.
57.
FraserH: HIV: From Care to Cure—Test, Treat, Defeat. The Barbados Advocate. 2017 (Col. The Barbados Advocate: Things That Matter).
58.
LandisC: In: Research Room (JosephR, ed.) UWItv: The University of the West Indies,. 2017. . Available at https://www.uwitv.org/intv/research-room-interview-prof-clive-landis, accessed May29, 2018.
59.
Declaration of Commitment by PANCAP Champions for Change to Contribute to Fast Track the End of AIDS in the Caribbean by 2030 [Press Release]. Pan Caribbean Partnership Against HIV/AIDS (PANCAP), 2017. Available at https://pancap.org/pancap-releases/a-declaration-of-commitment-by-pancap-champions-for-change-to-contribute-to-fast-track-the-end-of-aids-in-the-caribbean-by-2030, accessed May29, 2018.
60.
Pan Caribbean Partnership against HIV/AIDS (PANCAP) Regional Advocacy Strategy: 2017. Available at https://pancap.org/pc/pcc/media/pancap_document/PANCAP-Regional-Advocacy-Strategy.pdf, accessed May29, 2018.
61.
GreeneE: Scenarios for champions for change in support of ending AIDS by 2030. Champions for Change (C4C), 2017. Available at https://pancap.org/pc/pcc/media/pancap_event/Champions-for-Change-Scenarios-for-Action-REV-2-EG-13-09-17-3.pdf
62.
Communiqué – Dialogue Between Religious Leaders and Key Populations, February 7–9, 2018, Paramaribo, Suriname, 2018: The Right to Health and well-being for all so that no one is left behind: Pan Caribbean Partnership against HIV/AIDS (PANCAP); 2018. Available at https://pancap.org/pancap-releases/communique-dialogue-between-religious-leaders-and-key-populations-february-7-9-2018-paramaribo-suriname, accessed May29, 2018.
63.
KerriganD, BarringtonC, DonastorgY, PerezM, GalaiN: Abriendo Puertas: Feasibility and effectiveness a multi-level intervention to improve HIV outcomes among female sex workers living with HIV in the Dominican Republic. AIDS and Behavior, 2016; 20:1919–1927.
64.
DeroseKP, PayanDD, FulcarMA, et al.: Factors contributing to food insecurity among women living with HIV in the Dominican Republic: A qualitative study. PLoS One, 2017; 12:e0181568.
65.
LandisRC, Branch-BecklesSL, CrichlowS, HambletonIR, BestA: Ten year trends in community HIV viral load in Barbados: Implications for treatment as prevention. PLoS One, 2013; 8:e58590.
66.
AbayomiEA, LandisRC: Flow cytometry as the spearhead for delivering sustainable and versatile laboratory services to HIV-burdened health care systems of the developing world: A Caribbean model. Cytometry B Clin Cytom, 2008; 74Suppl 1:S80–S89.
67.
AlemnjiG, EdghillL, GuevaraG, et al.: Development and implementation of the Caribbean Laboratory Quality Management Systems Stepwise Improvement Process (LQMS-SIP) towards Accreditation. Afr J Lab Med, 2017; 6:496.
68.
AlemnjiGA, BranchS, BestA, et al.: Strengthening national laboratory health systems in the Caribbean Region. Glob Public Health, 2012; 7:648–660.
69.
LandisRC, Carmichael-SimmonsK, HambletonIR, BestA: HIV viral load trends in six eastern Caribbean countries utilizing a regional laboratory referral service: Implications for treatment as prevention. PLoS One, 2015; 10:e0125435.
70.
SharpPM, HahnBH: Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med, 2011; 1:a006841.
71.
ChitnisA, RawlsD, MooreJ: Origin of HIV type 1 in colonial French Equatorial Africa?. AIDS Res Hum Retroviruses, 2000; 16:5–8.
72.
PepinJ, LabbeAC: Noble goals, unforeseen consequences: Control of tropical diseases in colonial Central Africa and the iatrogenic transmission of blood-borne viruses. Trop Med Int Health, 2008; 13:744–753.
73.
TamCC, KhanMS, Legido-QuigleyH: Where economics and epidemics collide: Migrant workers and emerging infections. Lancet Lond Engl, 2016; 388:1374–1376.
74.
BurkleFMJr.: The politics of global public health in fragile states and ungoverned territories. PLOS Curr, 2017; 9: pii: ecurrents.dis.ba3beede71ca0746a0972aa3837ed618.
75.
van GorpE: Emerging infections in the global village: How HIV has prepared us. CCAS Caribbean International HIV Workshop, August 28, 2016 to September 1, 2016; Montego Bay, Jamaica. Available at http://www.hivgateway.com/entry/08f84c6f773c2d468b2fdbf71b6b090a/, accessed May29, 2018.
76.
GonsalvesG, StaleyP: Panic, paranoia, and public health—The AIDS epidemic's lessons for Ebola. N Engl J Med, 2014; 371:2348–2349.
77.
BurkleFMJr.: Global health security demands a strong international health regulations treaty and leadership from a highly resourced World Health Organization. Disaster Med Public Health Prep, 2015; 9:568–580.
78.
FairJM. Editorial: Biological engagement programs: Reducing threats and strengthening global health security Through Scientific Collaboration. Front Public Health, 2017; 5:148.
79.
UWI Tackles Caribbean Emergency Response to Zika and Beyond [press release]. The University of the West Indies, 2016. Available at http://sta.uwi.edu/news/releases/release.asp?id=1537, accessed May29, 2018.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
